{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:18:32Z","timestamp":1791613112388,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Municipal Natural Science Foundation","award":["7222171"],"award-info":[{"award-number":["7222171"]}]},{"name":"National Key Research and Development Program of China","award":["2021YFC2301100"],"award-info":[{"award-number":["2021YFC2301100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82101837;31800845"],"award-info":[{"award-number":["82101837;31800845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Viral load assessment for people living with HIV is key for monitoring treatment and achieving the 95-95-95. In this study, we aimed to assess the degree of viral suppression at different thresholds and treatment duration after the introduction of dolutegravir-based therapy in ten public hospitals in Sierra Leone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a cross-sectional study design to recruits patients aged 18 years or older between August 2022 and January 2023. Statistical analyses were performed using R-software. Logistic regression was used to assess factors independently associated with viral suppression. The level of significance was set at P\u2009&lt;\u20090.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 2,253 patients recruited, 1,720 (76%) were women and 1,705 (76%) were receiving a fixed dose combination of tenofovir, lamivudine and dolutegravir. The median age and duration of anti-retroviral therapy (ART) was 36.0 (IQR, 28.0\u201345.0) years and 40.9 (IQR, 14.4\u201379.6) months, respectively. Using a threshold of HIV RNA\u2009&lt;\u20091000 copies\/mL, 1,715 (88.4%) patients on ART for more than 6 months were virally suppressed. Viral suppression rates were higher with dolutegravir-based (1,277, 89.5%) than efavirenz-based (418, 86.2%) ART. HIV RNA was &lt;\u2009200 copies\/mL in 1,643 (84.6%) patients or &lt;\u200950 copies\/mL in 1,487 (76.6%) patients or between 50 and 999 copies\/mL in 228 (11.7%) patients. Viral suppression rates at different ART durations (months) were as follows: 84.2% (\u2264\u20093), 88.8% (4\u20136), 90.9% (6\u201312), and 88.1% (&gt;\u200912). Viral suppression rates were higher for patients aged 40 or older (40\u201350 years: aOR 2.05, 95%CI 1.41\u20133.04, P\u2009&lt;\u20090.01; 50\u201360 years: aOR 2.51, 95%CI 1.53\u20134.35, P\u2009&lt;\u20090.01; &gt;60 years: aOR 2.69, 95%CI 1.28\u20136.63, P\u2009=\u20090.02). Men had 49% lower odds of viral suppression than women (aOR 0.50, 95% CI 0.38\u20130.67, P\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We report a viral suppression rate of 88.4% among patients on treatment for at least 6 months, with higher rate of suppression with dolutegravir than efavirenz. Factors associated with virological suppression were age and gender, emphasizing the need for innovative differentiated ART delivery models to optimize viral suppression and achieve the 95% target.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-023-02245-2","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T14:02:32Z","timestamp":1701266552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey"],"prefix":"10.1186","volume":"20","author":[{"given":"Jin-Wen","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda N.","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umu","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlinda F.","family":"Jiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulai Tejan","family":"Jalloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Yendewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Lakoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"2245_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Fast-Track: Ending the AIDS Epidemic by 2030. UNAIDS. ; 2014. Available at: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/JC2686_WAD2014report_en.pdf. Accessed on: April 8, 2023."},{"key":"2245_CR2","unstructured":"World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. WHO. ; 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240031593. Accessed on: April 8, 2023."},{"issue":"28","key":"2245_CR3","doi-asserted-by":"publisher","first-page":"e3985","DOI":"10.1097\/MD.0000000000003985","volume":"95","author":"ND Labhardt","year":"2016","unstructured":"Labhardt ND, Bader J, Lejone TI, et al. Should viral load thresholds be lowered? Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings. Medicine. 2016;95(28):e3985. https:\/\/doi.org\/10.1097\/MD.0000000000003985.","journal-title":"Medicine"},{"issue":"4","key":"2245_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/infdis\/jir353","volume":"204","author":"B Taiwo","year":"2011","unstructured":"Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1\u2013Infected patients experiencing persistent low-level Viremia during First-Line Therapy. J Infect Dis. 2011;204(4):515\u201320. https:\/\/doi.org\/10.1093\/infdis\/jir353.","journal-title":"J Infect Dis"},{"issue":"17","key":"2245_CR5","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer C, Pozniak A. HIV Drug Resistance \u2014 an emerging threat to Epidemic Control. N Engl J Med. 2017;377(17):1605\u20137. https:\/\/doi.org\/10.1056\/NEJMp1710608.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"2245_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2055-6640(20)30347-2","volume":"4","author":"R de Waal","year":"2018","unstructured":"de Waal R, Lessells R, Hauser A, et al. HIV drug resistance in sub-saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. J Virus Erad. 2018;4(Suppl 2):55\u20138.","journal-title":"J Virus Erad"},{"issue":"12","key":"2245_CR7","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1093\/jac\/dkac338","volume":"77","author":"AJ Ntamatungiro","year":"2022","unstructured":"Ntamatungiro AJ, Kagura J, Weisser M, Francis JM. Pre-treatment HIV-1 drug resistance in antiretroviral therapy-naive adults in Eastern Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2022;77(12):3231\u201341. https:\/\/doi.org\/10.1093\/jac\/dkac338. PMID: 36225089.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2245_CR8","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/jac\/dkz134","volume":"74","author":"GA Yendewa","year":"2019","unstructured":"Yendewa GA, Sahr F, Lakoh S, Ruiz M, Pati\u00f1o L, Tabernilla A, Deen GF, Sesay M, Salata RA, Poveda E. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019;74(7):2024\u20139. https:\/\/doi.org\/10.1093\/jac\/dkz134. PMID: 30989237; PMCID: PMC6587425.","journal-title":"J Antimicrob Chemother"},{"key":"2245_CR9","unstructured":"Sierra Leone Demographic Health survey. 2019. Available at: https:\/\/dhsprogram.com\/pubs\/pdf\/FR365\/FR365.pdf. Accessed on March 24, 2023."},{"issue":"9","key":"2245_CR10","doi-asserted-by":"publisher","first-page":"ofy208","DOI":"10.1093\/ofid\/ofy208","volume":"5","author":"GA Yendewa","year":"2018","unstructured":"Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, Sahr F, Salata RA. High prevalence of late-stage Disease in newly diagnosed human immunodeficiency virus patients in Sierra Leone. Open Forum Infect Dis. 2018;5(9):ofy208. https:\/\/doi.org\/10.1093\/ofid\/ofy208. PMID: 30191158; PMCID: PMC6121223.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2245_CR11","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1186\/s12889-019-7614-3","volume":"19","author":"S Lakoh","year":"2019","unstructured":"Lakoh S, Jiba DF, Kanu JE, Poveda E, Salgado-Barreira A, Sahr F, Sesay M, Deen GF, Sesay T, Gashau W, Salata RA, Yendewa GA. Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study. BMC Public Health. 2019;19(1):1320. https:\/\/doi.org\/10.1186\/s12889-019-7614-3. PMID: 31638941; PMCID: PMC6805411.","journal-title":"BMC Public Health"},{"issue":"1","key":"2245_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12879-020-4862-x","volume":"20","author":"S Lakoh","year":"2020","unstructured":"Lakoh S, Rickman H, Sesay M, Kenneh S, Burke R, Baldeh M, Jiba DF, Tejan YS, Boyle S, Koroma C, Deen GF, Beynon F. Prevalence and mortality of cryptococcal Disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study. BMC Infect Dis. 2020;20(1):141. https:\/\/doi.org\/10.1186\/s12879-020-4862-x. PMID: 32059703; PMCID: PMC7023785.","journal-title":"BMC Infect Dis"},{"key":"2245_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijid.2020.04.038","volume":"96","author":"S Lakoh","year":"2020","unstructured":"Lakoh S, Jiba DF, Adekanmbi O, Poveda E, Sahr F, Deen GF, Foray LM, Gashau W, Hoffmann CJ, Salata RA, Yendewa GA. Diagnosis and treatment outcomes of adult Tuberculosis in an urban setting with high HIV prevalence in Sierra Leone: a retrospective study. Int J Infect Dis. 2020;96:112\u20138. Epub 2020 Apr 24. PMID: 32339724.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2245_CR14","doi-asserted-by":"publisher","first-page":"1947566","DOI":"10.1080\/16549716.2021.1947566","volume":"14","author":"S Lakoh","year":"2021","unstructured":"Lakoh S, Jiba DF, Vandy AO, Poveda E, Adekanmbi O, Murray MJS, Deen GF, Sahr F, Hoffmann CJ, Jacobson JM, Salata RA, Yendewa GA. Assessing eligibility for differentiated service delivery, HIV services utilization and virologic outcomes of adult HIV-infected patients in Sierra Leone: a pre-implementation analysis. Glob Health Action. 2021;14(1):1947566. PMID: 34404330; PMCID: PMC8381912.","journal-title":"Glob Health Action"},{"key":"2245_CR15","doi-asserted-by":"publisher","unstructured":"Rosen JG, Reynolds SJ, Galiwango RM, Kigozi G, Quinn TC, Ratmann O, Ndyanabo A, Nelson LJ, Nakigozi G, Nalugemwa M, Rucinski KB, Kennedy CE, Chang LW, Kagaayi J, Serwadda D, Grabowski MK. A moving target: impacts of lowering viral load suppression cutpoints on Progress towards HIV Epidemic Control Goals. medRxiv [Preprint]. 2023 Jan 20:2023.01.19.23284804. https:\/\/doi.org\/10.1101\/2023.01.19.23284804. PMID: 36711720; PMCID: PMC9882556.","DOI":"10.1101\/2023.01.19.23284804"},{"key":"2245_CR16","unstructured":"SSL. 2015: Sierra Leone Population Census. [(accessed on 14 August 2022)]. Available online: https:\/\/www.statistics.sl\/images\/StatisticsSL\/Documents\/Census\/2015\/sl_2015_phc_thematic_report_on_pop_structure_and_pop_distribution.pdf."},{"issue":"1","key":"2245_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1186\/s12889-020-09457-z","volume":"20","author":"E Marinda","year":"2020","unstructured":"Marinda E, Simbayi L, Zuma K, Zungu N, Moyo S, Kondlo L, Jooste S, Nadol P, Igumbor E, Dietrich C, Briggs-Hagen M. Towards achieving the 90-90-90 HIV targets: results from the South African 2017 national HIV survey. BMC Public Health. 2020;20(1):1375. https:\/\/doi.org\/10.1186\/s12889-020-09457-z. PMID: 32907565; PMCID: PMC7487872.","journal-title":"BMC Public Health"},{"key":"2245_CR18","doi-asserted-by":"publisher","unstructured":"Jensen MM, Byberg S, Jespersen S, Olesen JS, da Silva ZJ, Medina C, Krarup H, Wejse C, Erikstrup C, H\u00f8nge BL. The HIV care continuum of Guinea-Bissau; Progress towards the UNAIDS 90-90-90 targets for HIV-1 and HIV-2. Acta Trop. 2023; 241:106887. https:\/\/doi.org\/10.1016\/j.actatropica.2023.106887. Epub 2023 Mar 5. PMID: 36871618.","DOI":"10.1016\/j.actatropica.2023.106887"},{"key":"2245_CR19","doi-asserted-by":"publisher","unstructured":"Anito AA, Lenjebo TL, Woticha E, Solomon F. Magnitude of viral load suppression and Associated Factors among clients on antiretroviral therapy in Public Hospitals of Hawassa City Administration, Ethiopia. HIV AIDS (Auckl). 2022; 14:529\u201338. https:\/\/doi.org\/10.2147\/HIV.S387787. PMID: 36425750; PMCID: PMC9680672.","DOI":"10.2147\/HIV.S387787"},{"issue":"5","key":"2245_CR20","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","volume":"10","author":"J Dorward","year":"2023","unstructured":"Dorward J, Sookrajh Y, Khubone T, van der Molen J, Govender R, Phakathi S, Lewis L, Bottomley C, Maraj M, Lessells RJ, Naidoo K, Butler CC, Van Heerden R, Garrett N. Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study. Lancet HIV. 2023;10(5):e284\u201394. https:\/\/doi.org\/10.1016\/S2352-3018(23)00047-4. Epub 2023 Mar 28. PMID: 37001536.","journal-title":"Lancet HIV"},{"issue":"1","key":"2245_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/v15010018","volume":"15","author":"ENJ Semengue","year":"2022","unstructured":"Semengue ENJ, Fokam J, Etame NK, Molimbou E, Chenwi CA, Takou D, Mossiang L, Meledie AP, Yagai B, Nka AD, Dambaya B, Teto G, Ka\u2019e AC, Beloumou GA, Djupsa Ndjeyep SC, Abba A, Kengni AMN, Tommo Tchouaket MC, Bouba NP, Billong SC, Sosso SM, Colizzi V, Perno CF, Kouanfack C, Zoung-Kanyi Bissek AC, Eben-Moussi E, Santoro MM, Ceccherini-Silberstein F, Ndjolo A. Dolutegravir-based Regimen ensures high virological success despite prior exposure to Efavirenz-based First-LINE ART in Cameroon: an evidence of a successful transition model. Viruses. 2022;15(1):18. https:\/\/doi.org\/10.3390\/v15010018. PMID: 36680058; PMCID: PMC9866637.","journal-title":"Viruses"},{"issue":"1","key":"2245_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1186\/s12879-021-06722-3","volume":"21","author":"SB Abdullahi","year":"2021","unstructured":"Abdullahi SB, Ibrahim OR, Okeji AB, Yandoma RI, Bashir I, Haladu S, Idris SA, Oseni TIA, Suleiman BM, Yahaya M, Aworh MK, Sufiyan MB. Viral suppression among HIV-positive patients on antiretroviral therapy in northwestern Nigeria: an eleven-year review of tertiary care centre records, January 2009-December 2019. BMC Infect Dis. 2021;21(1):1031. https:\/\/doi.org\/10.1186\/s12879-021-06722-3. PMID: 34600477; PMCID: PMC8487150.","journal-title":"BMC Infect Dis"},{"key":"2245_CR23","unstructured":"Consolidated Guidelines on HIV Prevention., Diagnosis, Treatment and Care in Sierra Leone. Available at: https:\/\/www.nas.gov.sl\/publication\/164-consolidated-hiv-guidelines-on-hiv-prevention-october-2020. [Accessed on: May 17, 2023]."},{"key":"2245_CR24","doi-asserted-by":"publisher","unstructured":"Lakoh S, Bangura MM, Adekanmbi O, Barrie U, Jiba DF, Kamara MN, Sesay D, Jalloh AT, Deen GF, Russell JBW, Egesimba G, Yendewa GA, Firima E. Impact of COVID-19 on the utilization of HIV testing and Linkage Services in Sierra Leone: experience from Three Public Health Facilities in Freetown. AIDS Behav. 2023 Aug;29. https:\/\/doi.org\/10.1007\/s10461-023-04149-2. Epub ahead of print. PMID: 37642824.","DOI":"10.1007\/s10461-023-04149-2"},{"issue":"10189","key":"2245_CR25","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Guti\u00e9rrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J, PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)30418-0. Epub 2019 May 2. PMID: 31056293; PMCID: PMC6584382.","journal-title":"Lancet"},{"issue":"7","key":"2245_CR26","doi-asserted-by":"publisher","first-page":"e0271607","DOI":"10.1371\/journal.pone.0271607","volume":"17","author":"D Grace","year":"2022","unstructured":"Grace D, Stewart M, Blaque E, Ryu H, Anand P, Gaspar M, Worthington C, Gilbert M. Challenges to communicating the undetectable equals untransmittable (U = U) HIV prevention message: Healthcare provider perspectives. PLoS ONE. 2022;17(7):e0271607. https:\/\/doi.org\/10.1371\/journal.pone.0271607. PMID: 35862361; PMCID: PMC9302742.","journal-title":"PLoS ONE"},{"issue":"2","key":"2245_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/idr14020027","volume":"14","author":"T Prestileo","year":"2022","unstructured":"Prestileo T, Adriana S, Lorenza DM, Argo A. From undetectable equals untransmittable (U = U) to breastfeeding: is the Jump Short? Infect Dis Rep. 2022;14(2):220\u20137. https:\/\/doi.org\/10.3390\/idr14020027. PMID: 35447879; PMCID: PMC9030015.","journal-title":"Infect Dis Rep"},{"key":"2245_CR28","doi-asserted-by":"publisher","unstructured":"International Advisory Panel on HIV Care Continuum Optimization. IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14 Suppl 1:S3\u2013S34. https:\/\/doi.org\/10.1177\/2325957415613442. Epub 2015 Nov 2. PMID: 26527218.","DOI":"10.1177\/2325957415613442"},{"issue":"1","key":"2245_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","volume":"76","author":"O Elvstam","year":"2023","unstructured":"Elvstam O, Malmborn K, El\u00e9n S, Marrone G, Garc\u00eda F, Zazzi M, S\u00f6nnerborg A, B\u00f6hm M, Seguin-Devaux C, Bj\u00f6rkman P. Virologic failure following low-level Viremia and viral blips during antiretroviral therapy: results from a European Multicenter Cohort. Clin Infect Dis. 2023;76(1):25\u201331. https:\/\/doi.org\/10.1093\/cid\/ciac762. PMID: 36100984; PMCID: PMC9825828.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2245_CR30","doi-asserted-by":"publisher","first-page":"e0279479","DOI":"10.1371\/journal.pone.0279479","volume":"18","author":"N Nanyeenya","year":"2023","unstructured":"Nanyeenya N, Chang LW, Kiwanuka N, Nasuuna E, Nakanjako D, Nakigozi G, Kibira SPS, Nabadda S, Kiyaga C, Makumbi F. The association between low-level viraemia and subsequent viral non-suppression among people living with HIV\/AIDS on antiretroviral therapy in Uganda. PLoS ONE. 2023;18(1):e0279479. https:\/\/doi.org\/10.1371\/journal.pone.0279479. PMID: 36638086; PMCID: PMC9838846.","journal-title":"PLoS ONE"},{"issue":"1","key":"2245_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12981-021-00408-1","volume":"18","author":"J Maena","year":"2021","unstructured":"Maena J, Banke-Thomas A, Mukiza N, Kuteesa CN, Kakumba RM, Kataike H, Kizito S, Babirye JA, Nakalega R. Determinants of viral load non-suppression among adolescents in Mbale District, Eastern Rural Uganda. AIDS Res Ther. 2021;18(1):91. https:\/\/doi.org\/10.1186\/s12981-021-00408-1. PMID: 34863196; PMCID: PMC8642852.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"2245_CR32","doi-asserted-by":"publisher","first-page":"e068792","DOI":"10.1136\/bmjopen-2022-068792","volume":"13","author":"H Berihun","year":"2023","unstructured":"Berihun H, Bazie GW, Beyene A, Zewdie A, Kebede N. Viral suppression and associated factors among children tested for HIV viral load at Amhara Public Health Institute, Dessie Branch, Ethiopia: a cross-sectional study. BMJ Open. 2023;13(1):e068792. https:\/\/doi.org\/10.1136\/bmjopen-2022-068792. PMID: 36720566; PMCID: PMC9890760.","journal-title":"BMJ Open"},{"issue":"1","key":"2245_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4102\/sajhivmed.v23i1.1356","volume":"23","author":"BAY Elashi","year":"2022","unstructured":"Elashi BAY, van Wyk BE. Factors associated with viral suppression among adolescents on antiretroviral therapy in Free State province, South Africa. South Afr J HIV Med. 2022;23(1):1356. https:\/\/doi.org\/10.4102\/sajhivmed. PMID: 35923610; PMCID: PMC9257832.","journal-title":"South Afr J HIV Med"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02245-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T14:05:11Z","timestamp":1701266711000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02245-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2245"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02245-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Sierra Leone Ethics and Scientific Review Committee (SLESRC) of the Ministry of Health and Sanitation, Government of Sierra Leone in accordance with the relevant guidelines and regulations and declaration of Helsinki. Approval to conduct this study was granted by SLESRC, dated June 21, 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Written informed consent was obtained from individual participants before enrolling in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All the authors have no financial or proprietary interests in any material discussed in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}